The α-emitter 211At labeled to a monoclonal antibody has proven safe and effective in
treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete …

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing.
After extensive preclinical work with α-particle–emitting 211At, we performed a phase I trial …

Thirty-six patients with ovarian cancer were treated with intraperitoneal I-131 labeled
monoclonal antibodies to tumor associated antigens. The activity of I-131 administered was …

Purpose: The purpose of this study was to determine the feasibility and maximum tolerated
dose of 90Yttrium-CC49 (90Y-CC49) as the radioimmunotherapy (RIT) component of an ip …

The pharmacokinetics of intraperitoneal (ip) radiolabelled monoclonal antibody (MAb) was
studied in 35 patients receiving 40 ip injections. Eleven patients received 131I‐labelled …

Sixteen of 19 enrolled patients with minimal residual disease of ovarian cancer
(macroscopic disease< 5 mm or positive blind biopsies and/or positive peritoneal washing) …

A phase I trial was designed to examine the feasibility of combining interferon and Taxol with
intraperitoneal radioimmunotherapy (177Lu-CC49). Patients with recurrent or persistent …

The purpose of this study was to investigate the therapeutic efficacy of—and to estimate the
absorbed dose to—tumor cells from radioimmunotherapy (RIT) in an ovarian cancer model …

Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a
phase I/II trial of intraperitoneal177Lu-CC49 antibody. Methods. Patients had disease …

Advanced ovarian cancer is largely incurable, but initially it is frequently confined to the ip
space. We explored ip radioimmunotherapy in a mouse model of human ovarian cancer …